RECOVERY (Dexamethasone)
2021
Dexamethasone in Hospitalised Patients with COVID-19
In 6,425 hospitalised patients with COVID-19, dexamethasone 6 mg/day × 10 d reduced 28-day mortality compared with usual care, in patients requiring oxygen or ventilation.
Result
Efficacy: 28-day all-cause mortalityRR 0.83 (95% CI 0.75-0.93)
Below 1 favours dexamethasone 6 mg/day × 10 d, above 1 favours usual care.
- Absolute difference
- 2.8 points
- NNT
- 36
Absolute difference and NNT are derived from the event rates.
Also reported: Benefit only in patients on O₂ or mechanical ventilation.
- Subtopic
- Corticosteroids
- Design
- Adaptive platform RCT, UK
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- RECOVERY Collaborative Group. N Engl J Med. 2021;384(8):693-704.doi 10.1056/NEJMoa2021436
Discussion & critique
The single largest treatment effect in the COVID-19 pandemic; transformed inpatient management.
Discussed in podcasts
- Core IM | Internal Medicine Podcast · 2 episodes, latest 28 Jun 2023 (Listen)
- Freely Filtered, a NephJC Podcast · Freely Filtered 036: AKIKI-2, How soon is now? · 13 Jun 2021 (Listen)
- Critical Care Reviews Podcast · 3 episodes, latest 27 Dec 2020 (Listen)On Trialsgram
- The Skeptics Guide to Emergency Medicine · SGEM Xtra: EBM and the Changingman · 25 Jul 2020 (Listen)On Trialsgram
- This Week in Cardiology · 2 episodes, latest 26 Jun 2020 (Listen)